Evidence map›Paper›PMID 42881192›Full record

ArticleNature communications2026

MAP2-mediated integrin dysregulation reprograms cancer cell plasticity in hepatocellular carcinoma.

Ut Kei Lou, Tin-Lok Wong, Ianto Bosheng Huang, Ka-Hei Lam, Huajian Yu, Ki-Fong Man, Jia Jian Loh, Lei Zhou, Yuan Gao, Cheng-Han Yu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ut Kei LouSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.ORCID http://orcid.org/0009-0000-6287-4393
Tin-Lok WongSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.ORCID http://orcid.org/0000-0003-1147-7958
Ianto Bosheng HuangSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Ka-Hei LamSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Huajian YuSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Ki-Fong ManSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Jia Jian LohSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Lei ZhouPrecision Medicine Institute, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Yuan GaoState Key Laboratory of Cancer Biology, Biotechnology Centre, School of Pharmacy, Fourth Military Medical University, Xi'an, China.
Cheng-Han YuSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. chyu1@hku.hk.ORCID http://orcid.org/0000-0002-8821-8877
Stephanie MaSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. stefma@hku.hk.ORCID http://orcid.org/0000-0002-2029-7943

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting tumor cell plasticity is central to overcome drug resistance and metastasis. Through lineage-tracing and lineage-ablation studies, our team has previously shown hepatocellular carcinoma (HCC) cells marked by CD133 to represent a functional subset displaying dedifferentiated status with stemness traits, yet there are limited therapies effective for eradicating such resilient cell populations. Here, we explore the therapeutic potential of repurposing an existing drug estramustine phosphate (EMP) for targeting HCC plasticity through inhibiting MAP2, a gene uniquely enriched in CD133

Indexed as

Carcinoma, HepatocellularCell PlasticityIntegrinsLiver NeoplasmsAC133 AntigenAdaptor Proteins, Signal TransducingAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansNeoplastic Stem CellsSorafenibTranscription FactorsYAP-Signaling ProteinsAC133 AntigenAdaptor Proteins, Signal TransducingIntegrinsSorafenibTranscription FactorsYAP-Signaling Proteins

Identifiers

PMID42881192

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.